Tumor-targeting therapies represent a paradigm shift in cancer treatment. These therapies leverage the unique characteristics of cancer cells to improve therapeutic delivery to tumors while minimizing exposure to healthy tissue.
TwoStep Therapeutics leverages tumor-targeting technology based on a unique and modular Polyspecific Integrin-binding Peptide (PIP), which enables delivery of various payloads to virtually any solid tumor.
Unlike traditional agents, PIP binds selectively to five different integrin targets highly expressed on solid tumors. This unique multi-targeting feature allows PIP to target a wide range of tumor types, overcoming the limitations of single-antigen targeting approaches.
PIP preferentially binds to integrin conformations abundant in tumor tissue, enhancing specificity and safety.
